
Oncology Brothers: Practice-Changing Cancer Discussions
Oncology BrothersAudio
- Format:
- Podcast
- New episodes:
- Daily
- Typical length:
- about 20 minutes
- Latest episode:
About this show
The Oncology Brothers Podcast, led by Drs. Rahul and Rohit Gosain, is dedicated to bridging the gap between academic cancer centers and community oncology in the ever-evolving field of hematology & oncology. With a mission to disseminate crucial information to the medical community, this oncology podcast is not for medical advice but rather serves as a beacon for physicians, nurses, trainees, and advanced practice providers (APPs) involved in the care of cancer patients.
Drs. Rahul and Rohit Gosain, both esteemed oncologists, bring a wealth of experience and expertise from their general community practice to these discussions. Through short and engaging interviews with world-renowned researchers, clinicians, hematologists, and oncologists, they present practice-changing data in a concise, bite-sized format.
Get the latest FDA approvals news, oncology conference highlights, and treatment algorithms in 25 minutes or less. Conversations center around common cancers you see in your clinic like breast cancer, prostate cancer, kidney cancer, bladder cancer, lung cancer, and GI cancers. With new indications and approvals, we talk about how to incorporate this data in your day to day clinical practice.
Each episode includes visual presentations so you can follow along within the podcast players and on YouTube @oncbrothers. These visual tools and algorithms will provide an outline on what is covered in each episode. Immediately apply the latest insights and advancements in your daily practice, ensuring the delivery of optimal cancer care to patients within your local communities.
If you want to navigate the complexities of your hematology & oncology practice and stay current, the Oncology Brothers Podcast offers invaluable insights and practical takeaways to enhance your professional journey and improve patient outcomes. For more information, please visit: www.oncbrothers.com, and connect with us on Twitter/X/Instagram/TikTok: @oncbrothers, or email us at info@oncbrothers.com
Privacy Policy: https://oncbrothers.com/privacy-policy
Terms & Conditions: https://oncbrothers.com/terms-and-conditions
Covers: medical education, oncology, cancer treatment, lung cancer, hematology, clinical trials, genitourinary cancer, gastrointestinal cancer, cell therapy, continuing medical education
Show details and episodes come from the publisher's public feed at feed.podbean.com. Last updated . Names, artwork and text belong to their publishers.
Recently on this show
Summary of recent episodes, drawn from the publisher's feed.
Hosted by two community oncologists, this podcast shares short interviews with cancer experts on new treatment data for clinicians. Recent episodes cover rectal cancer treatment, uncommon EGFR lung mutations, bladder cancer approval, and ESMO 2026 lung and GI cancer highlights.
Cosmos
Similar in subject
- The Fellow on Call: The Heme/Onc Podcast
Both cover: hematology, oncology, clinical trials - Two Onc Docs
Both cover: lung cancer, oncology, medical education - The Uromigos
Both cover: genitourinary cancer, oncology
Similar shows
- Harrison's PodClass: Internal Medicine Cases and Board Prep
- Plenary Session
- Ones Ready
- Optimal Health Daily - Fitness and Nutrition
- Optimal Living Daily - Personal Development and Self-Improvement
- Optimal Protein Podcast with Vanessa Spina
- Oral-Maxillofacial Surgery Insights
- Orgasmic Enlightenment with Kim Anami
Explore more
Episodes
Follicular & Mantle Cell Lymphoma Treatment Algorithm: Dr. Jonathan Friedberg
· 22 min
In this episode of the Oncology Brothers podcast, we welcomed Dr. Jonathan Friedberg, a leading lymphoma expert, to discuss modern treatment approaches for follicular lymphoma and mantle cell lymphoma. Join us as we explored: - The diagnostic workup for follicular lymphoma, including the role of bone marrow biopsy and staging imaging - Treatment strategies for early-stage and symptomatic follicular lymphoma, including rituximab, obinutuzumab, and chemotherapy-based approaches - The evolving role of maintenance therapy and what recent studies have shown about progression-free and overall survival - New treatment options in relapsed/refractory follicular lymphoma, including tafasitamab and epcoritamab - The importance of TP53 testing in mantle cell lymphoma and the evolving role of BTK inhibitors in frontline treatment - The role of CAR T-cell therapy and bispecific antibodies in the evolving lymphoma treatment landscape This discussion provided practical insights into current treatment algorithms and emerging strategies for patients with follicular lymphoma and mantle cell lymphoma. Whether you're a hematologist, oncologist, advanced practice provider, nurse, pharmacist, trainee, or healthcare professional interested in lymphoma care, this episode offers an expert perspective on the rapidly evolving treatment landscape. If you found this discussion valuable, please like the video, subscribe to the Oncology Brothers, and share your thoughts in the comments. Listen us on: Spotify: https://open.spotify.com/show/31BXhY9FM4gPWG10WgE11o Follow us on social media: - X/Twitter: https://x.com/oncbrothers - Instagram: https://www.instagram.com/oncbrothers - Website: https://oncbrothers.com/ Subscribe for more expert discussions on hematology, oncology, lymphoma, immunotherapy, cellular therapy, targeted therapy, and advances in cancer care. #FollicularLymphoma #MantleCellLymphoma #Lymphoma #Hematology #OncologyBrothers
Not rated yetDiffuse Large B-cell Lymphoma (DLBCL) Treatment Algorithm: Dr. Mazyar Shadman
· 21 min
In this episode of the Oncology Brothers podcast we had a chance to discuss the current treatment landscape for diffuse large B-cell lymphoma (DLBCL) with Dr. Mazyar Shadman, from the Fred Hutch Cancer Center. We dived deep into frontline treatment options, including R-CHOP and polatuzumab-based regimens, and explored how to effectively risk stratify patients using the International Prognostic Index (IPI) score and the Hans algorithm. Dr. Shadman shared insights on the use of CAR T-cell therapy in both early and late relapsed settings, discussing the differences between axicabtagene ciloleucel (axi-cel) and lisocabtagene maraleucel (liso-cel), and the importance of bridging and holding therapies. Key topics covered in this episode: - Frontline treatment options for DLBCL - The role of polatuzumab in early-stage disease - Treatment paradigms for advanced-stage DLBCL - CAR T-cell therapy: who should receive it and when - The importance of community and tertiary care partnerships in improving patient access to innovative therapies Join us for an informative discussion that highlights the evolving landscape of DLBCL treatment and the critical role of collaboration in oncology care. Listen us on: Spotify: https://open.spotify.com/show/31BXhY9FM4gPWG10WgE11o Follow us on social media: - X/Twitter: https://x.com/oncbrothers - Instagram: https://www.instagram.com/oncbrothers - Website: https://oncbrothers.com/ Don't forget to like, subscribe, and share your thoughts in the comments! #DLBCL, #CARTtherapy, #RCHOP, #Polatuzumab, #OncologyBrothers
Not rated yetRevolution Medicines CEO Dr. Mark Goldsmith: Daraxonrasib dream to reality
· 26 min
Welcome to the Oncology Brothers podcast! In this episode, we dove deep into the groundbreaking advancements in pancreatic cancer treatment, focusing on the recent approval of daraxonrasib. Join us as we welcome Mark Goldsmith, MD, PhD, CEO of Revolution Medicines, who shared his inspiring journey from clinical practice to the biotech industry. Discover the challenges and triumphs behind bringing this first-in-class drug to market, and learn about the significant impact it has on patient outcomes. Keypoints: - Daraxonrasib is a first-in-class RAS inhibitor approved for the treatment of pancreatic cancer, targeting a mutation present in over 90% of cases. - The drug's development represents a major shift in pancreatic cancer, moving from a historically untreatable disease to a promising target for precision medicine. - Early clinical trial results demonstrated remarkable tumor shrinkage, driving urgency to bring the therapy to patients. - Management of side effects, including rash and gastrointestinal issues, is essential for optimal patient outcomes. - Ensuring patient access—despite high treatment costs—remains a priority, with patient assistance programs and insurance navigation support in place. - Future directions include combination therapies and the goal of transforming pancreatic cancer into a manageable chronic disease. We discussed the critical gaps between academic research and community practice, the importance of understanding side effects, and the financial implications of new therapies. Dr. Goldsmith also highlighted the future of pancreatic cancer treatment and the ongoing commitment to improving patient care. Whether you're a healthcare professional, a patient, or simply interested in the latest in oncology, this episode is packed with valuable insights and information. Listen us on: Spotify: https://open.spotify.com/show/31BXhY9FM4gPWG10WgE11o Follow us on social media: - X/Twitter: https://x.com/oncbrothers - Instagram: https://www.instagram.com/oncbrothers - Website: https://oncbrothers.com/ Don't forget to like, subscribe, and hit the notification bell for more episodes on the latest in cancer treatment and research! #PancreaticCancer, #Daraxonrasib, #RASinhibitor, #DrugDevelopment, #OncologyBrothers
Not rated yetCamizestrant + CDK 46i FDA Approval in Hormone Receptor Positive Breast Cancer SERENA-6
· 20 min
Welcome to another episode of the Oncology Brothers! In this episode, we dived into the recent FDA approval of camizestrant for the treatment of hormone receptor–positive metastatic breast cancer, based on the SERENA-6 trial. We welcomed Dr. Erica Mayer, a breast medical oncologist from the Dana-Farber Cancer Institute, who shared her insights on the trial's design, findings, and the significance of detecting ESR1 mutations before clinical progression. We discussed the implications of this approval, including the shift in treatment strategies, the importance of ctDNA monitoring, and the potential benefits for patient quality of life. Key topics covered in this episode: - Overview of the SERENA-6 trial and its findings - The role of ESR1 mutations in treatment resistance - The efficacy and safety profile of camizestrant - Practical insights on integrating next-generation sequencing (NGS) testing into clinical practice - Management of side effects, including bradycardia and QT prolongation Whether you're a healthcare professional or simply interested in the latest advancements in oncology, this episode is packed with valuable information. Listen us on: Spotify: https://open.spotify.com/show/31BXhY9FM4gPWG10WgE11o Follow us on social media: - X/Twitter: https://x.com/oncbrothers - Instagram: https://www.instagram.com/oncbrothers - Website: https://oncbrothers.com/ Don't forget to like, subscribe, and hit the notification bell for more updates from the Oncology Brothers! #Camizestrant, #SERENA6, #ESR1mutation, #BreastCancer, #OncologyBrothers
Not rated yetSURPASS-ET: FDA Approval of Ropeginterferon alfa-2b in Essential Thrombocythemia (ET)
· 22 min
Welcome to the Oncology Brothers podcast! In this episode, we talked about the most recent developments in the world of myeloproliferative neoplasms (MPNs), including the exciting FDA approvals of ropeginterferon alfa-2b for essential thrombocythemia (ET) and rusfertide for polycythemia vera (PV). The leading author Dr. John Mascarenhas, an MPN specialist from the Mount Sinai, New York, shared insights from the SURPASS-ET study, which paved the way for the official approval of ropeginterferon alfa-2b in ET. Dr. Mascarenhas discussed the study design, findings, and the implications of using ropeginterferon alfa-2b compared to traditional therapies like anagrelide and hydroxyurea. Key topics covered in this episode included: - Overview of the SURPASS-ET study and its significance - Efficacy and tolerability of ropeginterferon alfa-2b in ET - Side effect profiles of ropeginterferon alfa-2b vs anagrelide - The importance of monitoring JAK2 allele burden and its clinical relevance - Considerations for using ropeginterferon alfa-2b in frontline therapy for select patients Listen us on: Spotify: https://open.spotify.com/show/31BXhY9FM4gPWG10WgE11o Follow us on social media: - X/Twitter: https://x.com/oncbrothers - Instagram: https://www.instagram.com/oncbrothers - Website: https://oncbrothers.com/ Join us as we explore the evolving landscape of MPN treatment and the potential for disease modification with ropeginterferon alfa-2b. Don't forget to like, subscribe, and check out our other discussions on oncology topics! #EssentialThrombocythemia, #MPN, #Ropeginterferon, #SURPASSET, #OncologyBrothers
Not rated yetMyelofibrosis Treatment Algorithm Discussion: Dr. Nico Gagelmann
· 24 min
Welcome to the Oncology Brothers podcast! In this episode, we had the opportunity to dive deep into the treatment algorithm for myelofibrosis with Dr. Nico Gagelmann of Dana-Farber Cancer Institute. Join us as we explored: - The critical distinction between primary and secondary myelofibrosis and its implications for treatment - The essential workup needed before initiating therapy, including bone marrow biopsy and mutation analysis - Anemia management strategies, including the use of erythropoiesis-stimulating agents and the innovative drug luspatercept - The role of JAK inhibitors in treatment, including ruxolitinib, momelotinib, pacritinib, and fedratinib, and how to choose among them based on patient needs - The importance of spleen reduction and its correlation with patient outcomes and survival - Insights into the side effect profiles of various treatments and the future of myelofibrosis management Whether you're a healthcare professional or someone interested in oncology, this episode provides valuable information on navigating the complexities of myelofibrosis treatment. Listen us on: Spotify: https://open.spotify.com/show/31BXhY9FM4gPWG10WgE11o Follow us on social media: • X/Twitter: https://x.com/oncbrothers • Instagram: https://www.instagram.com/oncbrothers • Website: https://oncbrothers.com/ Don't forget to like, subscribe, and hit the notification bell for more episodes from the Oncology Brothers! #Myelofibrosis, #JAKinhibitors, #Hematology, #MPN, #OncologyBrothers
Not rated yetManaging Toxicities of Therapies in Polycythemia Vera (PV) / Essential Thrombocythemia (ET)
· 26 min
Welcome back to the Oncology Brothers podcast! In this episode, we were joined by the MPN specialists Drs. Brandi Reeves and Naveen Pemmaraju, to discuss the treatment options for polycythemia vera (PV) and essential thrombocythemia (ET). We dived deep into the side effect profiles and management strategies for key treatments, including: - Hydroxyurea: Learnt about dosing strategies, monitoring, and the importance of managing acute and chronic side effects such as leg ulcers and skin cancer risks - Ropeginterferon alfa-2b: Discover the benefits and potential side effects, including flu-like symptoms and neuropsychiatric issues, and how to approach dosing for patients with pre-existing conditions - Ruxolitinib: Understand the common side effects, including myelosuppression and weight gain, and the critical importance of tapering off the medication rather than stopping abruptly - Rusfertide: Get insights into this new hepcidin mimetic and its promising role in managing PV, along with potential side effects to monitor Join us for a comprehensive tox check discussion that aims to equip healthcare professionals with clinical pearls for managing these treatments effectively. Listen us on: Spotify: https://open.spotify.com/show/31BXhY9FM4gPWG10WgE11o Follow us on social media: - X/Twitter: https://x.com/oncbrothers - Instagram: https://www.instagram.com/oncbrothers - Website: https://oncbrothers.com/ Subscribe for more insights and updates from the Oncology Brothers! #PolycythemiaVera, #MPN, #EssentialThrombocythemia, #CytotoxicTherapies, #OncologyBrothers
Not rated yetVERIFY: FDA Approval of Rusfertide in Polycythemia Vera (PV) - Dr. Andrew Kuykendall
· 19 min
Welcome to the Oncology Brothers podcast! In this episode, we dived into the recent approval of rusfertide for polycythemia vera, based on the findings from the VERIFY study. We were joined by Dr. Andrew Kuykendall, an MPN specialist from the Moffitt Cancer Center, who shared insights on the drug's mechanism of action as a hepcidin mimetic and its clinical implications. Key topics discussed included: - The unique challenges of managing polycythemia vera, with balancing of erythrocytosis and iron deficiency - The design and findings of the VERIFY study, highlighting the significant reduction in the need for phlebotomy among patients treated with rusfertide - The potential for individualized patient care and the integration of rusfertide with existing cytoreductive therapies - Insights into dosing, side effects, and the drug's impact on patient quality of life Listen us on: Spotify: https://open.spotify.com/show/31BXhY9FM4gPWG10WgE11o Follow us on social media: - X/Twitter: https://x.com/oncbrothers - Instagram: https://www.instagram.com/oncbrothers - Website: https://oncbrothers.com/ Join us as we explore how rusfertide can change the treatment landscape for polycythemia vera and improve patient outcomes. Don't forget to like, subscribe, and hit the notification bell for more episodes! #Rusfertide, #PolycythemiaVera, #VERIFYstudy, #MPN, #Hematology
Not rated yetPolycythemia vera (PV) and Essential thrombocythemia (ET) Treatment Algorithm: Dr. Aaron Gerds
· 28 min
Welcome to the Oncology Brothers podcast! In this episode, we are joined by Dr. Aaron Gerds, a hematologist from the Cleveland Clinic, to discuss the current treatment algorithms for myeloproliferative neoplasms (MPNs), specifically focusing on polycythemia vera (PV) and essential thrombocythemia (ET). Join us as we delved into: - The diagnostic criteria for PV and ET, including the significance of JAK2 mutations and erythropoietin (EPO) levels - The role of bone marrow biopsies in diagnosing and managing these conditions - Treatment options for PV, including hydroxyurea, ropeginterferon alfa-2b, and ruxolitinib, as well as the approval of rusfertide - The importance of risk stratification based on patient age and history of thrombosis - The management of side effects associated with various treatment options - The clinical utility of monitoring JAK2 allele burden and its implications for patient management - Insights into the treatment landscape for ET, including the use of antiplatelet therapy and the role of acquired Von Willebrand disease Whether you're a healthcare professional or someone interested in the latest advancements in oncology, this episode provides valuable insights into the complexities of managing PV and ET. Listen us on: Spotify: https://open.spotify.com/show/31BXhY9FM4gPWG10WgE11o Follow us on social media: - X/Twitter: https://x.com/oncbrothers - Instagram: https://www.instagram.com/oncbrothers - Website: https://oncbrothers.com/ Don't forget to like, subscribe, and hit the notification bell for more episodes on the latest in hematological and oncological care! #PolycythemiaVera, #EssentialThrombocythemia, #MPN, #JAK2, #OncologyBrothers
Not rated yetMultiple Myeloma Management - Partners in Practice with Dr. Ajai Chari Team from UCSF
· 21 min
Welcome to the Oncology Brothers podcast! In this episode of our Partners in Practice series, we dived into the world of multiple myeloma treatment. We had the opportunity to engage with the dedicated team from UCSF, including Dr. Ajai Chari, a myeloma specialist, nurse practitioner Samantha Shenoy, NP, and clinical nurse Jenny Truong, RN. In this insightful discussion, we covered: - The current standard of care for newly diagnosed multiple myeloma patients, focusing on quadruple therapy - The role of anti-CD38 therapies like daratumumab and isatuximab in treatment regimens - Patient expectations regarding side effects and the importance of supportive care - The dynamics of teamwork in oncology, emphasizing communication and collaboration among healthcare professionals Whether you're a healthcare professional, a patient, or simply interested in the latest advancements in cancer care, this episode offers valuable insights into the complexities of treating multiple myeloma. Listen us on: Spotify: https://open.spotify.com/show/31BXhY9FM4gPWG10WgE11o Follow us on social media: - X/Twitter: https://x.com/oncbrothers - Instagram: https://www.instagram.com/oncbrothers - Website: https://oncbrothers.com/ Don't forget to like, subscribe, and hit the notification bell for more episodes from the Oncology Brothers! #MultipleMyeloma, #QuadTherapy, #Daratumumab, #Isatuximab, #OncologyBrothers
Not rated yetHERIZON-GEA-01: FDA Approval of Zanidatamab + Tislelizumab for HER2+ Esophageai/GEJ/Gastric Adeno
· 16 min
We had a chance to dive into one of the most significant advancements in the treatment of HER2-positive gastroesophageal junction (GEJ) and gastric adenocarcinoma. In this episode, we discussed the groundbreaking HERIZON-GEA-01 study that led to the approval of zanidatamab, a novel bispecific HER2-directed antibody. We welcomed Dr. Nataliya Uboha, a GI medical oncologist from the University of Wisconsin, who shared her insights on the study's design, findings, and the implications for clinical practice. Learn about the importance of biomarker testing, the mechanism of action of zanidatamab, and how it compares to traditional therapies like trastuzumab. Key topics covered in this episode: - Overview of the HERIZON-GEA-01 study and its findings - Mechanism of action of zanidatamab - Comparison of treatment regimens and overall survival benefits - Management of side effects, including diarrhea and infusion reactions - The role of PD-L1 testing in treatment decisions Whether you're a healthcare professional or simply interested in the latest in oncology, this episode provides valuable insights into the evolving landscape of treatment for HER2-positive upper GI malignancies. Listen us on: - Spotify: https://open.spotify.com/show/31BXhY9FM4gPWG10WgE11o Follow us on social media: - X/Twitter: https://x.com/oncbrothers - Instagram: https://www.instagram.com/oncbrothers - Website: https://oncbrothers.com/ Don't forget to like, subscribe, and check out our other discussions on FDA approvals, treatment algorithms, and challenging cases! #GastricCancer, #HER2positive, #Zanidatamab, #HERIZONGEA01, #OncologyBrothers
Not rated yetRapid Fire Rounds - Multiple Myeloma Management with Dr. Joseph Mikhael
· 25 min
Welcome to the Oncology Brothers podcast and our new series, Rapid Fire Rounds! In this episode, we were joined by Dr. Joseph Mikhael, a myeloma specialist from the City of Hope, to answer 10–12 community-sourced questions on multiple myeloma management. The panel covers: - Frontline therapy: Quadruplet therapy, carfilzomib vs bortezomib, and high-risk disease definitions - Maintenance strategies: Lenalidomide alone vs daratumumab-lenalidomide vs carfilzomib-lenalidomide, with insights from the ENDURANCE, ATLAS trials - Relapsed/refractory disease: Sequencing CAR T-cell therapy, bispecific antibodies (teclistamab + daratumumab), and the newly approved cereblon modulators (CELMoDs) like mezigdomide - CAR-T logistics: The critical distinction between holding therapy (pre-collection) and bridging therapy (post-collection) - Supportive care: IVIG, antiviral/antifungal prophylaxis, and monitoring for ICANS - MRD testing: Current role in clinical practice and its use as an endpoint for drug approval This episode is packed with practical, actionable insights for community oncologists managing myeloma day-to-day. Listen us on: Spotify: https://open.spotify.com/show/31BXhY9FM4gPWG10WgE11o Follow us on social media: - X/Twitter: https://x.com/oncbrothers - Instagram: https://www.instagram.com/oncbrothers - Website: https://oncbrothers.com/ Don't forget to like, subscribe, and hit the notification bell for more Rapid Fire Rounds from the Oncology Brothers! #MultipleMyeloma, #CARTtherapy, #MRD, #CELMoD, #OncologyBrothers
Not rated yetEXCALIBER-RRMM - Iberdomide/Dara/Dex FDA Approval for R/R Multiple Myeloma: Dr. Sagar Lonial
· 20 min
Welcome to the Oncology Brothers podcast! In this episode, we were joined by Dr. Sagar Lonial, a myeloma specialist from the Emory University, to discuss the recent FDA approval of iberdomide, a novel cereblon modulator (CELMoDs), in combination with daratumumab and dexamethasone for the treatment of relapsed and refractory multiple myeloma. Join us as we dive into: - The significance of the EXCALIBER-RRMM study that led to the approval of iberdomide - What makes cereblon modulators different from existing immunomodulatory agents (IMiDs) and their potential benefits - The study design, findings, and the implications of minimal residual disease (MRD) as a primary endpoint for approval - Who the ideal candidates for iberdomide are and how it fits into the current treatment landscape - The side effect profile of iberdomide compared to traditional therapies and management strategies - Insights on monitoring disease status and the future of cereblon modulators in combination with other therapies This episode is packed with valuable information for healthcare professionals and anyone interested in the latest advancements in multiple myeloma treatment. Listen us on: Spotify: https://open.spotify.com/show/31BXhY9FM4gPWG10WgE11o Follow us on social media: - X/Twitter: https://x.com/oncbrothers - Instagram: https://www.instagram.com/oncbrothers - Website: https://oncbrothers.com/ Don't forget to like, subscribe, and hit the notification bell for more updates from the Oncology Brothers! #CELMoDs, #MultipleMyeloma, #EXCALIBERstudy, #MRD, #OncologyBrothers
Not rated yetManaging Toxicities of Androgen Receptor Pathway Inhibitor (ARPI) in Prostate Cancer
· 24 min
Welcome to the Oncology Brothers podcast! In this episode, we discussed the world of androgen receptor pathway inhibitors (ARPIs) in prostate cancer as part of our Tox Check series. Joined by esteemed guests Dr. Alicia Morgans, a GU medical oncologist from Dana-Farber Cancer Institute, and Dr. Christopher M. Pieczonka, a urologist from US Urology Partners, the discussion covered the common side effects associated with ARPIs, including cardiac issues, cognitive changes, and more. Key topics included: - An overview of approved ARPIs, focusing on abiraterone, apalutamide, darolutamide, and enzalutamide - The importance of monitoring side effects and strategies to mitigate them - Insights from recent studies, highlighting the impact of these medications on patient quality of life - A discussion on the role of shared decision-making in treatment options for prostate cancer patients Whether you're a healthcare professional or someone interested in prostate cancer treatment, this episode aims to equip you with valuable knowledge to better manage patient care. Listen us on: Spotify: https://open.spotify.com/show/31BXhY9FM4gPWG10WgE11o Follow us on social media: • X/Twitter: https://x.com/oncbrothers • Instagram: https://www.instagram.com/oncbrothers • Website: https://oncbrothers.com/ Don't forget to like, subscribe, and hit the notification bell for more insightful discussions from the Oncology Brothers! #ProstateCancer, #ARPI, #SideEffectManagement, #SharedDecisionMaking, #OncologyBrothers
Not rated yetChallenging Cases in Myelodysplastic Syndrome (MDS) - Dr. Amer Zeidan
· 25 min
Join us with as we dive into two challenging cases of myelodysplastic syndromes (MDS) in this episode featuring Dr. Amer Zeidan, from the Yale School of Medicine. The discussion focused on real-life scenarios from community settings, exploring treatment decisions in both frontline settings and cases of disease progression. In the first case, we examined a 74-year-old gentleman with persistent anemia and discussed the implications of his diagnosis, treatment options like erythropoiesis-stimulating agents (ESAs) and luspatercept, and the importance of timely intervention. The conversation highlighted the evolving landscape of MDS treatment, including the significance of molecular risk stratification and the potential for improved patient outcomes. The second case featured a 67-year-old woman whose disease has progressed despite initial treatment with luspatercept. Dr. Zeidan shared insights on the next steps, including the use of hypomethylating agents (HMAs) , the role of transplant, and the management of side effects associated with these therapies. Tune in for an informative discussion that not only addressed treatment strategies but also emphasized the importance of patient-centered care and the need for ongoing monitoring and support. Don't forget to like, subscribe, and share your thoughts with us! If there are specific topics or cases you'd like us to cover in future episodes, reach out to us. Episode Highlights: - Overview of MDS and its treatment landscape - Case discussions on treatment decisions for anemia and disease progression - Insights on the use of luspatercept and hypomethylating agents - Management of side effects and the importance of patient education Listen us on: Spotify: https://open.spotify.com/show/31BXhY9FM4gPWG10WgE11o Apple Podcast: https://podcasts.apple.com/us/podcast/oncology-brothers-practice-changing-cancer-discussions/id1653340966 Follow us on social media: • X/Twitter: https://x.com/oncbrothers • Instagram: https://www.instagram.com/oncbrothers • Website: https://oncbrothers.com/ Thanks for tuning in! We are the Oncology Brothers. #MDS, #MyelodysplasticSyndrome, #HMAs, #HemeMalignancy, #OncologyBrothers
Not rated yetTreatment Algorithm of Myelodysplastic Syndrome (MDS) in 2026 - Dr. Thomas LeBlanc
· 27 min
Welcome to the Oncology Brothers podcast! In this episode, we were joined by Thomas LeBlanc, MD MA, from the Duke Cancer Institute to discuss the treatment algorithm for myelodysplastic syndrome (MDS). We dived deep into the importance of risk stratification in MDS, exploring lower-risk, intermediate-risk, and higher-risk categories. Dr. LeBlanc shared insights on the role of next-generation sequencing (NGS) and the Revised International Prognostic Scoring System (IPSS-R) in guiding treatment decisions. Key topics included: - Treatment options for lower-risk MDS, including the use of erythropoiesis-stimulating agents (ESAs) and luspatercept - The significance of ring sideroblasts and del(5q) in treatment selection - The management of anemia, thrombocytopenia, and neutropenia in MDS patients - The emerging role of imetelstat for heavily transfusion-dependent patients and its unique side effects Join us as we unpacked the complexities of MDS treatment and emphasize the importance of personalized care for patients. Listen us on: Spotify: https://open.spotify.com/show/31BXhY9FM4gPWG10WgE11o Follow us on social media: - X/Twitter: https://x.com/oncbrothers - Instagram: https://www.instagram.com/oncbrothers - Website: https://oncbrothers.com/ Don't forget to like, subscribe, and hit the notification bell for more insightful discussions in oncology! #MDS, #MyelodysplasticSyndrome, #RiskStratification, #OncologyBrothers
Not rated yetPancreatic Cancer Management - Partners in Practice with Dr. Tim Brown & Ms. Heather Kline
· 19 min
Join us in this insightful episode of our new series, Partners in Practice. We delved into the critical role of teamwork in cancer care, focusing on the treatment landscape of metastatic pancreatic cancer. In this episode, we were joined by Dr. Timothy Brown, a GI medical oncologist from UT Southwestern, and Ms. Heather Kline, a GI-focused nurse practitioner. Together, we explored the latest treatment options, including modified FOLFIRINOX, NALIRIFOX, gemcitabine with nab-paclitaxel, and the emerging role of novel therapies like RAS inhibitors. Key topics include: - Overview of current treatment paradigms for metastatic pancreatic cancer - Discussion of side effects and patient management strategies - The importance of communication and collaboration within the oncology team - Insights into the future of pancreatic cancer treatment and the potential of new therapies Whether you're a healthcare professional, a patient, or simply interested in oncology, this episode offers valuable perspectives on delivering compassionate and effective cancer care. Listen us on: Spotify: https://open.spotify.com/show/31BXhY9FM4gPWG10WgE11o Follow us on social media: - X/Twitter: https://x.com/oncbrothers - Instagram: https://www.instagram.com/oncbrothers - Website: https://oncbrothers.com/ Don't forget to like, subscribe, and hit the notification bell for more episodes from the Oncology Brothers! #PancreaticCancer, #PartnersInPractice, #RASinhibitors, #OncologyBrothers
Not rated yetTreatment Algorithm of Late Relapsed/Refractory Multiple Myeloma (RRMM)
· 24 min
In this episode of the Oncology Brothers podcast, we dived deep into the complexities of late relapse refractory multiple myeloma treatment. Joined by Maximilian Merz, MD, a myeloma specialist from the Memorial Sloan Kettering Cancer Center, the discussion covered the evolving treatment landscape, including the use of CAR-T cell therapies, bispecific antibodies, and the importance of assessing BCMA expression. Key topics included: - The current treatment algorithms for late relapse refractory multiple myeloma - The significance of antigen expression in guiding treatment decisions - The role of bispecific antibodies like teclistamab and talquetamab - Managing side effects and improving patient quality of life - The importance of collaboration between community hematologists and tertiary care centers Join us as we explored the latest advancements in myeloma treatment and the critical role of patient education and support in navigating this challenging disease. Don't forget to check out our previous episodes on newly diagnosed multiple myeloma and early relapse refractory disease! Listen us on: Spotify: https://open.spotify.com/show/31BXhY9FM4gPWG10WgE11o Follow us on social media: - X/Twitter: https://x.com/oncbrothers - Instagram: https://www.instagram.com/oncbrothers - Website: https://oncbrothers.com/ Subscribe for more insights and updates on oncology treatments! #MultipleMyeloma, #CART, #BispecificAntibody, #RelapsedMyeloma, #OncologyBrothers
Not rated yetTreatment Algorithm of Early Relapsed/Refractory Multiple Myeloma (RRMM)
· 22 min
In this episode of the Oncology Brothers podcast we continued our treatment algorithm series, focusing on early relapsed/refractory multiple myeloma (RRMM). We were joined by Dr. Shaji Kumar, a myeloma specialist from the Mayo Clinic, who shared his insights into current evidence-based treatment strategies for patients whose disease has progressed after frontline therapy. Key topics discussed included: - The current standard of care for frontline multiple myeloma, including quadruplet therapy and maintenance strategies - The role of CAR T-cell therapy and bispecific antibodies, including teclistamab and talquetamab, in early relapsed/refractory multiple myeloma - Treatment selection based on patient age, prior therapy, drug exposure, and disease biology - The importance of shared decision-making and incorporating patient preferences into treatment planning - Recent clinical trial data and emerging therapies shaping the future of multiple myeloma care This episode provides practical insights into managing early relapsed/refractory disease and navigating today's evolving treatment landscape. Listen us on: Spotify: https://open.spotify.com/show/31BXhY9FM4gPWG10WgE11o Follow us on social media: - X/Twitter: https://x.com/oncbrothers - Instagram: https://www.instagram.com/oncbrothers - Website: https://oncbrothers.com/ Subscribe for more expert discussions on multiple myeloma, hematologic malignancies, cellular therapies, bispecific antibodies, and precision oncology. #MultipleMyeloma #CART #BispecificAntibodies #Hematology #Oncology
Not rated yetENDURANCE Trial - Time-limited Lenalidomide Maintenance for Standard Risk Myeloma
· 16 min
Welcome to the Oncology Brothers podcast! In this episode, we dived into the latest advancements in multiple myeloma treatment, focusing on the practice changing ENDURANCE trial. Joined by esteemed guests Dr. Shaji Kumar and Dr. Vincent Rajkumar from Mayo Clinic, they discussed the new time limited approach being the standard of care for maintenance therapy in standard-risk multiple myeloma patients. Key topics include: - Overview of the ENDURANCE trial and its implications for clinical practice - The significance of limiting lenalidomide maintenance therapy to two years - The role of minimal residual disease (MRD) testing in treatment decisions - Insights on high-risk cytogenetics and future directions for therapy This episode is a must-listen for community oncologists and anyone interested in the evolving landscape of cancer treatment. Tune in to learn how these findings can impact patient care and improve outcomes! Listen us on: Spotify: https://open.spotify.com/show/31BXhY9FM4gPWG10WgE11o Follow us on social media: - X/Twitter: https://x.com/oncbrothers - Instagram: https://www.instagram.com/oncbrothers - Website: https://oncbrothers.com/ Don't forget to like, subscribe, and check out our other episodes for more discussions on treatment algorithms, conference highlights, and challenging cases in oncology. #MultipleMyeloma, #ENDURANCE, #Lenalidomide, #MRD, #OncologyBrothers
Not rated yet